Clinical Trials
72
Active:0
Completed:67
Trial Phases
5 Phases
Early Phase 1:7
Phase 1:38
Phase 2:17
+2 more phases
Drug Approvals
542
CANADA:269
FDA:4
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (72 trials with phase data)• Click on a phase to view related trials
Phase 1
38 (52.8%)Phase 2
17 (23.6%)Phase 3
9 (12.5%)Early Phase 1
7 (9.7%)Phase 4
1 (1.4%)A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
Phase 1
Completed
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 1000
- Registration Number
- NCT06733402
- Locations
- 🇺🇸
Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States
A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 476
- Registration Number
- NCT06673654
- Locations
- 🇺🇸
Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States
A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.
Phase 1
Completed
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 382
- Registration Number
- NCT06673641
- Locations
- 🇺🇸
Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States
A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.
Phase 1
Completed
- Conditions
- Tinea Versicolor
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 430
- Registration Number
- NCT06305637
- Locations
- 🇺🇸
Taro, Hawthorne, New York, United States
A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
Phase 1
Completed
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Taro Pharmaceuticals USA
- Target Recruit Count
- 762
- Registration Number
- NCT06063473
- Locations
- 🇺🇸
Taro Pharmaceuticals USA Inc., Hawthorne, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
No news found